Prostate cancer markers

• US 20040253609A1
• Filed: 01/06/2004
• Published: 12/16/2004
• Est. Priority Date: 07/28/2000
• Status: Abandoned Application

• Current Assignee: Incyte Corporation
• Original Assignee: Incyte Corporation
• Inventors: Turner, Christopher M., Faris, Mary
• Application Number:
  US10/752,986
• Publication Number:
  US 20040253609A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.

Claims

1. A composition comprising a plurality of cDNAs that are differentially expressed in prostate cancer and selected from SEQ ID NOs:

1-3, 5, 6, 8, 10-15, 17-19, 21, 23-28, 30, 32, 34-36, 38, 40, 42-45, 47-50, 52, 53, 55, 56, 58-65, 67, 68, 70-73, 75, 76, 78-86, 88-90, 92-97, 99-101 or their complements.

2. The composition of claim 1, wherein each of the cDNAs is differentially regulated between non-metastatic and metastatic prostate cancer and is selected from SEQ ID NOs:

1-3, 5, 6, 8, 10-15, 17-19, 21, 23-28, 30, 32, 34-36, 38, 40, 42-45, 47-50, 52, 53, 55, 56, 58-65, 67, 68, 70-73, 75.

3. The composition of claim 1, wherein each of the cDNAs is differentially regulated between prostate cancer and normal prostate and is selected from SEQ ID NOs:

76, 78-86, 88-90, 92-97, 99-101.

4. The composition of claim 1, wherein the cDNAs are immobilized on a substrate.

5. A high throughput method for detecting differential expression of one or more cDNAs in a sample containing nucleic acids, the method comprising:

(a) hybridizing the substrate of claim 4 with nucleic acids of the sample, thereby fomming one or more hybridization complexes;

(b) detecting the hybridization complexes; and

(c) comparing the hybridization complexes with those of a standard, wherein differences between the standard and sample hybridization complexes indicate differential expression of cDNAs in the sample.

6. The method of claim 5, wherein the nucleic acids of the sample are amplified prior to hybridization.

7. The method of claim 5, wherein the sample is from a subject with prostate cancer and comparison with a standard defines an early, mid, or late stage of that disease.

8. A high throughput method of screening a plurality of molecules or compounds to identify a ligand which specifically binds a cDNA, the method comprising:

(a) combining the composition of claim 1 with the plurality of molecules or compounds under conditions to allow specific binding; and

(b) detecting specific binding between each cDNA and at least one molecule or compound, thereby identifying a ligand that specifically binds to each cDNA.

9. The method of claim 8 wherein the plurality of molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, transcription factors, repressors, and regulatory proteins.

10. An isolated cDNA encoding a protein comprising the amino acid sequence of SEQ ID NO:

36.

11. A vector containing the cDNA of claim 10.

12. A host cell containing the vector of claim 11.

13. A method for producing a protein, the method comprising the steps of:

(a) culturing the host cell of claim 12 under conditions for expression of protein; and

(b) recovering the protein from the host cell culture.

14. A protein or a portion thereof produced by the method of claim 13.

15. A high-throughput method for using a protein to screen a plurality of molecules or compounds to identify at least one ligand which specifically binds the protein, the method comprising:

(a) combining the protein of claim 14 with the plurality of molecules or compounds under conditions to allow specific binding; and

(b) detecting specific binding between the protein and a molecule or compound, thereby identifying a ligand which specifically binds the protein.

16. The method of claim 15 wherein the plurality of molecules or compounds is selected from DNA molecules, RNA molecules, peptide nucleic acid molecules, mimetics, peptides, proteins, agonists, antagonists, antibodies or their fragments, immunoglobulins, inhibitors, drug compounds, and pharmaceutical agents.

17. A method of using a protein to produce an antibody, the method comprising:

a) immunizing an animal with the protein of claim 14 under conditions to elicit an antibody response;

b) isolating animal antibodies; and

c) screening the isolated antibodies with the protein, thereby identifying an antibody which specifically binds the protein.

18. A method of purifying an antibody, the method comprising:

a) combining the protein of claim 14 with a sample under conditions to allow specific binding;

b) recovering the bound protein; and

c) separating the protein from the antibody, thereby obtaining purified antibody.